1Morandi P, Rouzier R, Altundag K, et al. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach[J]. Cancer, 2004, 101(7): 1482.
2Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of Letrozole (Femara) versus Tamoxifen as first-line therapy for postmanopausal women with advanced breast cancer: results of a phase Ⅲ study of the international Letrozole Breast Cancer Group[J]. J Clinical Oncology, 2001, 19(10): 2596.
3Miller W R. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer[J]. Semin Oncol, 2003, 30(4 Suppl14): 3.
4Mitropoulou T N, Tzanakakis G N, Kletsas D, et al. Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP22 and MMP29) by human epithelial breast cancer cells[J]. Int J Cancer, 2003, 104(2): 155.
5Ellis M J, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status[J]. Cancer Res, 2003, 63(19): 6523.
6Breast International Group. Letrozole vs Tamixifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer BIG1-98: A prosoective randomized double-blind phase Ⅲ study, 2005. 26.
7ATAC Trialists′ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial After Completion of 5 Years′ Adjuvant Treatment for breast cancer[J]. Obstet Gynecol Surv, 2005, 60(5): 307.
8Goldirsch A, Wood W, Gellber R, et al. Meeting high-ighes: Updated expert international consensus on the primary therapy of early breast cancer[J]. J Clin Oncol, 2003, 21: 3357.
9Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial[J]. N Engl J Med, 2001, 93: 684.
10Goss P E, Ingle J N, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer[J]. N Engl J Med, 2003, 349: 1793.
同被引文献4
1Saphner T, Tormey D C, Gray R. et al. Annual hazard rates of recurrence for breast cancer after primary therapy [ J ]. J Clin Oneol, 1996, 14: 2738.
2Mouridsen H, Gershanovieh M, Sun Y, et al, Superior efficacy of Letrozole (Femara) versus Tamoxifen as firstline therapy for postmenopausal women with advanced breast cancer: resuits of a phase Ⅲ study of the international Letrozole Breast Cancer Group[J]. J Clin Oneol, 2001, 19(10):2596.
3Goss P E, Ingle J N, Martlno S D O, et al. A Randomized Trial of Letrczole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer[J]. N Engl J Med, 2003, 349: 19.
